New Trade Alert: Onconova Therapeutics, Inc. (NASDAQ: ONTX)
Cancer affects millions of people annually, and expenditures for cancer care are expected to increase over the years.
The American Cancer Society estimates there will be approximately 1.74M cancer cases for 2018, or around 4,700 new cancer diagnoses per day.
According to the National Cancer Institute, National expenditures for cancer care in the U.S. alone totaled nearly $125B in 2010 and could reach over $150B in 2020.
The rising costs of treating cancer as well as the adverse affects associated with treatments like chemotherapies and traditional cytotoxic medications, has encouraged patients to seek alternative methods, in particular, small molecule targeted cancer therapies.
Unlike traditional treatments which can harm normal cells during treatment, small molecule targeted cancer therapy destroys cancer cells with high precision while normal cells are able to survive, thus making this treatment potentially more effective than traditional methods.
Small molecule targeted cancer treatments have an array of applications in various cancers, such as melanoma, prostate cancer, lymphoma, breast cancer, multiple myeloma and all other cancers.